Bispecific Antibody Platform
Immune checkpoint modulation (PD‑1, CTLA‑4, 4‑1BB, CD28, CD47)
PreclinicalActive
Key Facts
Indication
Immune checkpoint modulation (PD‑1, CTLA‑4, 4‑1BB, CD28, CD47)
Phase
Preclinical
Status
Active
Company
About PrecisemAb Biotech
A Taiwan biotech delivering safer, tumor‑selective antibodies via a protease‑activated lock technology.
View full company profile